Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Samsung Biologics | Seoul | Healthcare | Pharmaceuticals | ₩68.4T | 64.8x | 0 | ₩964,000 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.1% Upside | Upgrade to Pro+ | |
Alteogen | KOSDAQ | Healthcare | Pharmaceuticals | ₩16.95T | -4,450.9x | 32.14 | ₩311,000 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.8% Upside | Upgrade to Pro+ | |
Yuhan | Seoul | Healthcare | Pharmaceuticals | ₩8.83T | 57x | 0.55 | ₩116,900 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1.8% Upside | Upgrade to Pro+ | |
Yuhan | Seoul | Healthcare | Pharmaceuticals | ₩8.83T | 57x | 0.55 | ₩104,700 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sk Biopharma | Seoul | Healthcare | Pharmaceuticals | ₩8.06T | 140.6x | 0.84 | ₩104,100 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.5% Upside | Upgrade to Pro+ | |
SK Bioscience Co | Seoul | Healthcare | Pharmaceuticals | ₩3.8T | -84.6x | 0.44 | ₩47,150 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.1% Upside | Upgrade to Pro+ | |
Hanmi Pharm Co | Seoul | Healthcare | Pharmaceuticals | ₩3.46T | 22.1x | 0.96 | ₩264,500 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hugel | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.88T | 26.7x | 0.33 | ₩270,000 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.5% Upside | Upgrade to Pro+ | |
Celltrion Pharm | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.37T | 84x | ₩53,600 | -6.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Sam Chun Dang Pharm | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.27T | 459.2x | 0.48 | ₩97,900 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pharma Reaserch Products | KOSDAQ | Healthcare | Pharmaceuticals | ₩2.25T | 27.2x | 0.46 | ₩219,500 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.6% Upside | Upgrade to Pro+ | |
Hanmi Science | Seoul | Healthcare | Pharmaceuticals | ₩2.12T | 21.2x | 11.3 | ₩30,000 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hanall Biopharma | Seoul | Healthcare | Pharmaceuticals | ₩1.81T | -286.1x | 1.42 | ₩35,400 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.7% Upside | Upgrade to Pro+ | |
ST Pharm | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.75T | 52.1x | 0.31 | ₩87,400 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.3% Upside | Upgrade to Pro+ | |
GC Biopharma | Seoul | Healthcare | Pharmaceuticals | ₩1.71T | -86.1x | 0.08 | ₩152,500 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.4% Upside | Upgrade to Pro+ | |
Nature Cell | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.48T | -287.2x | 0.4 | ₩21,700 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Daewoong Pharma | Seoul | Healthcare | Pharmaceuticals | ₩1.43T | 14.3x | 0.11 | ₩122,000 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Caregen | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.2T | 33.9x | -7.78 | ₩23,750 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -42.9% Downside | Upgrade to Pro+ | |
HLB Life Science | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.18T | 15.2x | 0.09 | ₩10,040 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Chong Kun Dang Pharma | Seoul | Healthcare | Pharmaceuticals | ₩1.15T | 6.3x | 0.16 | ₩90,800 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HK Inno.N | KOSDAQ | Healthcare | Pharmaceuticals | ₩1.06T | 26.1x | ₩36,500 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Oscotec | KOSDAQ | Healthcare | Pharmaceuticals | ₩893.67B | -190.5x | -2.56 | ₩23,400 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Mezzion Pharma | KOSDAQ | Healthcare | Pharmaceuticals | ₩885.42B | -61.7x | -1.4 | ₩29,100 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Daewoong | Seoul | Healthcare | Pharmaceuticals | ₩856.66B | 7x | 2.96 | ₩20,450 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.7% Upside | Upgrade to Pro+ | |
Medy-Tox | KOSDAQ | Healthcare | Pharmaceuticals | ₩834.68B | 81.7x | 5.48 | ₩125,000 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HLB Therapeutics | KOSDAQ | Healthcare | Pharmaceuticals | ₩810B | -28.4x | 0.11 | ₩10,260 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Dongkook Pharmaceutical | KOSDAQ | Healthcare | Pharmaceuticals | ₩721.96B | 12x | 0.4 | ₩16,200 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.1% Upside | Upgrade to Pro+ | |
Green Cross Holdings | Seoul | Healthcare | Pharmaceuticals | ₩699.91B | -10.3x | 0.01 | ₩23,750 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Green Cross | Seoul | Healthcare | Pharmaceuticals | ₩699.91B | -10.3x | 0.01 | ₩15,460 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Boryung Pharm | Seoul | Healthcare | Pharmaceuticals | ₩666.56B | 10.8x | 0.09 | ₩9,970 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.2% Upside | Upgrade to Pro+ |